![](http://www.ecns.cn/hd/2021/02/07/04360b0b384c43468dfa495cd762d5c2.jpg)
A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, displays a dose of COVID-19 inactivated vaccine in Schering bottle package in Beijing, capital of China, Dec. 23, 2020. China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)
![](http://www.ecns.cn/hd/2021/02/07/632dff092f29462abd322b53ab4f3a8e.jpg)
A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, cultivates Vero cells for production of COVID-19 inactivated vaccines in Beijing, capital of China, March 23, 2020. China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)
![](http://www.ecns.cn/hd/2021/02/07/6ed424c56eb84766b4077be1d8b6b6e7.jpg)
A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, cultivates Vero cells for production of COVID-19 inactivated vaccines in Beijing, capital of China, March 23, 2020. China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)
![](http://www.ecns.cn/hd/2021/02/07/6b97ba50449945f8a1916a28c9252f63.jpg)
Staff members of Sinovac Biotech, a Chinese biopharmaceutical company, carry out simulated novel coronavirus inoculation at a high-level biosafety zone of a stock solution workshop to be put into production of COVID-19 inactivated vaccines in Beijing, capital of China, July 15, 2020. China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)
![](http://www.ecns.cn/hd/2021/02/07/a29886fb3cb8438b8c2898b5f1adbd12.jpg)
A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, works in the quality inspection lab of COVID-19 inactivated vaccines in Beijing, capital of China, Dec. 23, 2020. China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)
![](http://www.ecns.cn/hd/2021/02/07/68adb0db16824241ac6e61d0ffc36f6c.jpg)
A staff member of Sinovac Biotech, a Chinese biopharmaceutical company, displays two doses of COVID-19 inactivated vaccine in prefilled syringes in Beijing, capital of China, Dec. 23, 2020. China's National Medical Products Administration on Friday granted conditional market approval to CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, the company said on Saturday. (Xinhua/Zhang Yuwei)